LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients
详细信息 查看全文
- 作者：Chang Shua ; 1 ; Tianmei Zengb ; 1 ; Shouhong Gaoa ; Tianyi Xiaa ; Lifeng Huanga ; Feng Zhanga ; zhangfeng@smmu.edu.cn" class="auth_mail" title="E-mail the corresponding author ; Wansheng Chena ; chenwansheng@smmu.edu.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：MM ; multiple myeloma ; SEER ; surveillance epidemiology and end results ; BTZ ; bortezomib ; CTX ; cyclophosphamide ; ADM ; adriamycin ; LND ; lenalidomide ; THD ; thalidomide ; MEL ; melphalan ; DXM ; dexamethasone ; PDN ; prednisone ; LC&ndash ; MS/MS ; high performance liquid chromatography-tandem mass spectrometry ; FLC ; fluconazole ; VDL ; vindoline ; ACN ; acetonitrile ; FA ; formic acid ; QC ; quality control ; LLOQ ; lower limit of quantification ; CV ; variation coefficients ; RE ; relative error ; PPT ; protein precipitatio
- 刊名：Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences
- 出版年：2016
- 出版时间：15 August 2016
- 年：2016
- 卷：1028
- 期：Complete
- 页码：111-119
- 全文大小：731 K
文摘
- •
A LC–MS/MS method for simultaneous quantification of drugs in serum which were commonly used in multiple myeloma patients.
- •
Sample pretreatment was efficient and reliable with a solid phase extraction method.
- •
The methodology validation was strictly implemented in accordance with the newest edition Chinese Pharmacopoeia, as well as FDA guidelines.
- •
The method had been successful applied in clinical sample determination and contributed to the ongoing clinical development of MM treatment.